Basic Information
| LncRNA/CircRNA Name | NORAD |
| Synonyms | NORAD, LINC00657, ASHGA5P032173 |
| Region | GRCh38_20:36045622-36050960 |
| Ensemble | ENSG00000260032 |
| Refseq | NR_027451 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic cancer |
| ICD-0-3 | C25 |
| Methods | qPCR, Western blot etc. |
| Sample | cell lines (SW1990, Capan-1, PANC-1, AsPC-1, CFPAC-1, MIAPaCa-2, BxPC-3) |
| Expression Pattern | up-regulated |
| Function Description | NORAD is highly expressed in pancreatic cancer tissues and upregulated in hypoxic conditions. NORAD upregulation is correlated with shorter overall survival in pancreatic cancer patients. Furthermore, NORAD overexpression promoted the migration and invasion of pancreatic carcinoma cells, while NORAD depletion inhibited EMT and metastasis in vitro and in vivo. In particular, NORAD may function as a ceRNA to regulate the expression of the small GTP binding protein RhoA through competition for hsa-miR-125a-3p, thereby promoting EMT. |
| Pubmed ID | 29121972 |
| Year | 2017 |
| Title | Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer |
External Links
| Links for NORAD | GenBank HGNC NONCODE |
| Links for pancreatic cancer | OMIM COSMIC |